Cargando…

Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes

BACKGROUND: The role of splenectomy to diagnose and treat hematologic disease continues to evolve. In this single-center retrospective review, we describe modern morbidity, mortality, and long-term outcomes associated with splenectomy for benign and malignant hematologic disorders. METHODS: We analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Alobuia, Wilson M, Perrone, Kenneth, Iberri, David J, Brar, Rondeep S, Spain, David A, Forrester, Joseph D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479208/
https://www.ncbi.nlm.nih.gov/pubmed/32939448
http://dx.doi.org/10.1016/j.sopen.2020.06.004
_version_ 1783580221517070336
author Alobuia, Wilson M
Perrone, Kenneth
Iberri, David J
Brar, Rondeep S
Spain, David A
Forrester, Joseph D
author_facet Alobuia, Wilson M
Perrone, Kenneth
Iberri, David J
Brar, Rondeep S
Spain, David A
Forrester, Joseph D
author_sort Alobuia, Wilson M
collection PubMed
description BACKGROUND: The role of splenectomy to diagnose and treat hematologic disease continues to evolve. In this single-center retrospective review, we describe modern morbidity, mortality, and long-term outcomes associated with splenectomy for benign and malignant hematologic disorders. METHODS: We analyzed all nontrauma splenectomies performed for benign or malignant hematologic disorders from January 2009 to September 2018. Variables collected included demographics, preexisting comorbidities, laboratory results, intra- and postoperative features, and long-term follow-up. Outcomes of interest included postoperative complications, 30-day mortality, and overall mortality. RESULTS: We identified 161 patients who underwent splenectomy for hematologic disorders. Median age was 54 years (range 19–94), and 83 (52%) were female. Splenectomy was performed for 95 (59%) patients with benign hematologic disorders and for 66 (41%) with malignant conditions. Most splenectomies were laparoscopic (76%), followed by laparoscopic hand assisted (11%), open (8%), and laparoscopic converted to open (6%). Median follow-up was 761 days (interquartile range: 179–2025 days). Major complications occurred in 21 (13%) patients. Three (2%) patients died within 30 days; 16 (9%) died more than 30 days after operation, none from surgical complications, with median time to death of 438 days (interquartile range: 231–1497 days). Among malignant cases, only preoperative thrombocytopenia predicted death (odds ratio = 5.8, 95% confidence interval = 1.1–31.8, P = .04). For benign cases, increasing age was associated with inferior survival (odds ratio = 2.3, 95% confidence interval = 1.0–5.1, P = .05). CONCLUSION: Splenectomy remains an important diagnostic and therapeutic option for patients with benign and malignant hematologic disorders and can be performed with a low complication rate. Despite considerable burden of comorbid disease in these patients, early postoperative mortality was uncommon.
format Online
Article
Text
id pubmed-7479208
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74792082020-09-15 Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes Alobuia, Wilson M Perrone, Kenneth Iberri, David J Brar, Rondeep S Spain, David A Forrester, Joseph D Surg Open Sci Article BACKGROUND: The role of splenectomy to diagnose and treat hematologic disease continues to evolve. In this single-center retrospective review, we describe modern morbidity, mortality, and long-term outcomes associated with splenectomy for benign and malignant hematologic disorders. METHODS: We analyzed all nontrauma splenectomies performed for benign or malignant hematologic disorders from January 2009 to September 2018. Variables collected included demographics, preexisting comorbidities, laboratory results, intra- and postoperative features, and long-term follow-up. Outcomes of interest included postoperative complications, 30-day mortality, and overall mortality. RESULTS: We identified 161 patients who underwent splenectomy for hematologic disorders. Median age was 54 years (range 19–94), and 83 (52%) were female. Splenectomy was performed for 95 (59%) patients with benign hematologic disorders and for 66 (41%) with malignant conditions. Most splenectomies were laparoscopic (76%), followed by laparoscopic hand assisted (11%), open (8%), and laparoscopic converted to open (6%). Median follow-up was 761 days (interquartile range: 179–2025 days). Major complications occurred in 21 (13%) patients. Three (2%) patients died within 30 days; 16 (9%) died more than 30 days after operation, none from surgical complications, with median time to death of 438 days (interquartile range: 231–1497 days). Among malignant cases, only preoperative thrombocytopenia predicted death (odds ratio = 5.8, 95% confidence interval = 1.1–31.8, P = .04). For benign cases, increasing age was associated with inferior survival (odds ratio = 2.3, 95% confidence interval = 1.0–5.1, P = .05). CONCLUSION: Splenectomy remains an important diagnostic and therapeutic option for patients with benign and malignant hematologic disorders and can be performed with a low complication rate. Despite considerable burden of comorbid disease in these patients, early postoperative mortality was uncommon. Elsevier 2020-08-16 /pmc/articles/PMC7479208/ /pubmed/32939448 http://dx.doi.org/10.1016/j.sopen.2020.06.004 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Alobuia, Wilson M
Perrone, Kenneth
Iberri, David J
Brar, Rondeep S
Spain, David A
Forrester, Joseph D
Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes
title Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes
title_full Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes
title_fullStr Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes
title_full_unstemmed Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes
title_short Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes
title_sort splenectomy for benign and malignant hematologic pathology: modern morbidity, mortality, and long-term outcomes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479208/
https://www.ncbi.nlm.nih.gov/pubmed/32939448
http://dx.doi.org/10.1016/j.sopen.2020.06.004
work_keys_str_mv AT alobuiawilsonm splenectomyforbenignandmalignanthematologicpathologymodernmorbiditymortalityandlongtermoutcomes
AT perronekenneth splenectomyforbenignandmalignanthematologicpathologymodernmorbiditymortalityandlongtermoutcomes
AT iberridavidj splenectomyforbenignandmalignanthematologicpathologymodernmorbiditymortalityandlongtermoutcomes
AT brarrondeeps splenectomyforbenignandmalignanthematologicpathologymodernmorbiditymortalityandlongtermoutcomes
AT spaindavida splenectomyforbenignandmalignanthematologicpathologymodernmorbiditymortalityandlongtermoutcomes
AT forresterjosephd splenectomyforbenignandmalignanthematologicpathologymodernmorbiditymortalityandlongtermoutcomes